Current therapeutic options for Alzheimer's disease

Current Genomics

Volumn 8, Issue 8, 2007, Pages 550-558

  Lleó, Alberto ^a  

^a HOSPITAL DE LA SANTA CREU I SANT PAU   (Spain)

Author keywords

Acetylcholinesterase inhibitors; Alzheimer's; Amyloid; Anti inflammatory drugs; Behavioral symptoms; Memantine; Treatment; Vitamin E

Indexed keywords

ACETYLCHOLINE; ALPHA TOCOPHEROL; CHOLINESTERASE INHIBITOR; CIMETIDINE; CITALOPRAM; DONEPEZIL; ERYTHROMYCIN; ESCITALOPRAM; FLUOXETINE; FLURBIPROFEN; FLUVOXAMINE; GALANTAMINE; GINKGO BILOBA EXTRACT; HALOPERIDOL; KETOCONAZOLE; MEMANTINE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; NEUROPROTECTIVE AGENT; NONSTEROID ANTIINFLAMMATORY AGENT; OLANZAPINE; PAROXETINE; PLACEBO; QUETIAPINE; RISPERIDONE; RIVASTIGMINE; SELEGILINE; SERTRALINE; TACRINE; UNINDEXED DRUG; ZIPRASIDONE;

ABDOMINAL PAIN; ALZHEIMER DISEASE; ASTHENIA; BEHAVIOR; CLINICAL TRIAL; COGNITION; CONFUSION; DEGENERATIVE DISEASE; DEVELOPED COUNTRY; DIARRHEA; DIZZINESS; DREAM; DRUG APPROVAL; DRUG BIOAVAILABILITY; DRUG DOSE INCREASE; DRUG HALF LIFE; DRUG INDUCED HEADACHE; DRUG SAFETY; FATIGUE; HALLUCINATION; HUMAN; INSOMNIA; LIFE EXPECTANCY; MENTAL DISEASE; NAUSEA; NEUROLOGIC DISEASE; PATHOGENESIS; PREVALENCE; REVIEW; SIDE EFFECT; SOMNOLENCE; SYNAPSE; TIME TO MAXIMUM PLASMA CONCENTRATION; VOMITING; WEIGHT REDUCTION;

EID: 41549164761     PISSN: 13892029     EISSN: None     Source Type: Journal    
DOI: 10.2174/138920207783769549     Document Type: Review

References (118)

1. Hebert, L.E., Scherr, P.A., Bienias, J.L., Bennett, D.A. Evans, D.A. Alzheimer disease in the US population. Prevalence estimates using the 2000 census. Arch. Neurol. 2003, 60: 1119-1112.
2. Wimo, A., Winblad, B., Aguero Torres, H. von Strauss, E. The magnitude of dementia occurrence in the world. Alzheimer Dis. Assoc. Disord. 2003, 17: 63-67.
3. Wolfe, M.S. Therapeutic strategies for Alzheimer's disease. Nat. Rev. Drug Discov. 2002, 1: 859-866.
4. Tanzi, R.E. Alzheimer's disease and related dementias: the road to intervention. Exp. Gerontol. 2000, 35: 433-437.
5. Doody, R.S., Stevens, J.C., Beck, C., Dubinsky, R.M., Kaye, J.A., Gwyther, L., Mobs, R.C., Thal, L.J., Whitehouse, P.J., DeKosky, S.T. Cummings, J.L. Practice parameter: management of dementia (an evidence-based review). Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2001, 56: 1154-1166.
6. Bartus, R.T., Dean, R.L., 3rd, Beer, B. Lippa, A.S. The cholinergic hypothesis of geriatric memory dysfunction. Science 1982, 217: 408-414.
7. Francis, P.T., Palmer, A.M., Snape, M. Wilcock, G.K. The cholinergic hypothesis of Alzheimer's disease: a review of progress. J Neurol. Neurosurg. Psychiatry 1999, 66: 137-147.
8. Cummings, J.L. Kaufer, D. Neuropsychiatric aspects of Alzheimer's disease: the cholinergic hypothesis revisited. Neurology 1996, 47: 876-883.
9. Davies, P. Maloney, AJ. Selective loss of central cholinergic neurons in Alzheimer's disease. Lancet 1976, 2: 1403.
10. Perry, E.K., Perry, R.H., Smith, C.J., Purohit, D., Bonham, J., Dick, D.J., Candy, J.M., Edwardson, JA. Fairbaim, A. Cholinergic receptors in cognitive disorders. Can. J. Neurol. Sci. 1986, 13: 521-527.
11. Perry, E.K., Tomlinson, B.E., Blessed, G., Bergmann, K., Gibson, P.H. Perry, R.H. Correlation of cholinergic abnormalities with senile plaques and mental test scores in senile dementia. BMJ 1978, 2: 1457-1459.
12. Whitehouse, P.J., Price, D.L., Clark, A.W., Coyle, J.T. DeLong, M.R. Evidence for selective loss of cholinergic neurons in the nucleus basalis. Ann. Neurol. 1981, 10: 122-126.
13. Gilmor, M.L., Erickson, J.D., Varoqui, H., Hersh, L.B., Bennett, D.A., Cochran, E.J., Mufson, E.J. Levey, A.I. Preservation of nucleus basalis neurons containing choline acetyltransferase and the vesicular acetylcholine transporter in the elderly with mild cognitive impairment and early Alzheimer's disease. J Comp. Neurol. 1999, 411: 693-704.
14. Giacobini, E. Cholinesterases: new roles in brain function and in Alzheimer's disease. Neurochem. Res. 2003, 28: 515-522.
15. Farlow, M.R. Clinical pharmacokinetics of galantamine. Clin. Pharmacokinet. 2003, 42: 1383-1392.
16. Summers, W.K., Majovski, L.V., Marsh, G.M., Tachiki, K. Kling, A. Oral tetrahydroaminoacridine in long-term treatment of senile dementia, Alzheimer type. N. Engl. J. Med. 1986, 315: 1241-1245.
17. Knapp, M.J., Knopman, D.S., Solomon, P.R., Pendlebury, W.W., Davis, C.S. Gracon, S.I. A 30-week randomized controlled trial of high-dose tacrine in patients with Alzheimer's disease. The Tacrine Study Group. JAMA 1994, 271: 985-991.
18. Rogers, S.L. Friedhoff, L.T. The efficacy and safety of donepezil in patients with Alzheimer's disease: results of a US Multicentre, Randomized, Double-Blind, Placebo-Controlled Trial. The Donepezil Study Group. Dementia 1996, 7: 293-303.
19. Rogers, S.L., Farlow, M.R., Doody, R.S., Mobs, R. Friedhoff, L.T. A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Alzheimer's disease. Donepezil Study Group. Neurology 1998, 50: 136-145.
20. Rogers, S.L., Doody, R.S., Mobs, R.C. Friedhoff, L.T. Donepezil improves cognition and global function in Alzheimer disease: a 15-week, double-blind, placebo-controlled study. Donepezil Study Group. Arch. Intern. Med. 1998, 158: 1021-1031.
21. Burns, A., Rossor, M., Hecker, J., Gauthier, S., Petit, H., Moller, H.J., Rogers, S.L. Friedhoff, LT. The effects of donepezil in Alzheimer's disease - results from a multinational trial. Dement. Geriatr. Cogn. Disord. 1999, 10: 237-244.
22. Winblad, B., Engedal, K., Soininen, H., Verhey, F., Waldemar, G., Wimo, A., Wetterholm, A.L., Zhang, R., Haglund, A. Subbiah, P. A 1-year, randomized, placebo-controlled study of donepezil in patients with mild to moderate AD. Neurology 2001, 57: 489-495.
23. Greenberg, S.M., Tennis, M.K., Brown, L.B., Gomez-Isla, T., Hayden, D.L., Schoenfeld, D.A., Walsh, K.L., Corwin, C., Daffner, K.R., Friedman, P., Meadows, M.E., Sperling, R.A. Growdon, J.H. Donepezil therapy in clinical practice: a randomized crossover study. Arch. Neurol. 2000, 57: 94-99.
24. Rosler, M., Anand, R., Cicin-Sain, A., Gauthier, S., Agid, Y., Dal-Bianco, P., Stahelin, H.B., Hartman, R. Gharabawi, M. Efficacy and safety of rivastigmine in patients with Alzheimer's disease: international randomised controlled trial. BMJ 1999, 318: 633-638.
25. Farlow, M., Anand, R., Messina, J. Jr., Hartman, R. Veach, J. A 52-week study of the efficacy of rivastigmine in patients with mild to moderately severe Alzheimer's disease. Eur. Neurol. 2000, 44: 236-241.
26. Wilcock, G.K., Lilienfeld, S. Gaens, E. Efficacy and safety of galantamine in patients with mild to moderate Alzheimer's disease: multicentre randomised controlled trial. Galantamine International-1 Study Group. BMJ 2000, 321: 1445-1449.
27. Raskind, M.A., Peskind, E.R., Wessel, T. Yuan, W. Galantamine in AD: A 6-month randomized, placebo-controlled trial with a 6-month extension. The Galantamine USA-1 Study Group. Neurology 2000, 54: 2261-2268.
28. Tariot, P.N., Solomon, P.R., Morris, J.C., Kershaw, P., Lilienfeld, S. Ding, C. A 5-month, randomized, placebo-controlled trial of galantamine in AD. The Galantamine USA-10 Study Group. Neurology 2000, 54: 2269-2276.
29. Rosen, W.G., Mobs, R.C. Davis, K.L. A new rating scale for Alzheimer's disease. Am. J. Psychiatry 1984, 141: 1356-1364.
30. Folstein, M.F., Folstein, S.E. McHugh, P.R. Mini-mental state exam. J. Psychiatr. Res. 1975, 12: 189-198.
31. Knopman, D.S., Knapp, M.J., Gracon, S.I. Davis, C.S. The Clinician Interview-Based Impression (CIBI): a clinician's global change rating scale in Alzheimer's disease. Neurology 1994, 44: 2315-2321.
32. Trinh, N.H., Hoblyn, J., Mohanty, S. Yaffe, K. Efficacy of cholinesterase inhibitors in the treatment of neuropsychiatric symptoms and functional impairment in Alzheimer disease: a meta-analysis. JAMA 2003, 289: 210-216.
33. Cummings, J.L., Mega, M., Gray, K., Rosenberg-Thompson, S., Carusi, D.A. Gombein, J. The neuropsychiatric inventory: comprehensive assessment of psychopathology in dementia. Neurology 1994, 44: 2308-2314.
34. Mobs, R.C., Doody, R.S., Morris, J.C., Ieni, J.R., Rogers, S.L., Perdomo, C.A. Pratt, R.D. A 1-year, placebo-controlled preservation of function survival study of donepezil in AD patients. Neurology 2001, 57: 481-488.
35. Geldmacher, D.S., Provenzano, G., McRae, T., Mastey, V. Ieni, J.R. Donepezil is associated with delayed nursing home placement in patients with Alzheimer's disease. J. Am. Geriatr. Soc. 2003, 51: 937-944.
36. Feldman, H., Gauthier, S., Hecker, J., Vellas, B., Emir, B., Mastey, V. Subbiah, P. Efficacy of donepezil on maintenance of activities of daily living in patients with moderate to severe Alzheimer's disease and the effect on caregiver burden. J. Am. Geriatr. Soc. 2003, 51: 737-744.
37. Sano, M., Wilcock, G.K., van Baelen, B. Kavanagh, S. The effects of galantamine treatment on caregiver time in Alzheimer's disease. Int. J. Geriatr. Psychiatry 2003, 18: 942-950.
38. Karlawish, J.H. Whitehouse, P.J. Is the placebo control obsolete in a world after donepezil and vitamin E? Arch. Neurol. 1998, 55: 1420-1424.
39. Rogers, S.L., Doody, R.S., Pratt, R.D. Ieni, J.R. Long-term efficacy and safety of donepezil in the treatment of Alzheimer's disease: final analysis of a US multicentre open-label study. Eur. Neuropsychopharmacol. 2000, 10: 195-203.
40. Raskind, M.A., Peskind, ER., Truyen, L., Kershaw, P. Damaraju, C.V. The cognitive benefits of galantamine are sustained for at least 36 months. Arch. Neurol. 2004, 61: 252-256.
41. Doody, R.S., Geldmacher, D.S., Gordon, B., Perdomo, C.A. Pratt, R.D. Open-label, multicenter, phase 3 extension study of the safety and efficacy of donepezil in patients with Alzheimer disease. Arch. Neurol. 2001, 58: 427-433.
42. Courtney, C., Farrell, D., Gray, R., Hills, R., Lynch, L., Sellwood, E., Edwards, S., Hardyman, W., Raftery, J., Crome, P., Lendon, C., Shaw, H. Bentham, P. Long-term donepezil treatment in 565 patients with Alzheimer's disease (AD2000): randomised double-blind trial. Lancet 2004, 363: 2105-2115.
43. Rondi-Reig, L., Libbey, M., Eichenbaum, H. Tonegawa, S. CA1-specific N-methyl-D-aspartate receptor knockout mice are deficient in solving a nonspatial transverse patterning task. Proc. Natl. Acad. Sci. U. S. A. 2001, 98: 3543-3548.
44. Katsuki, H., Izumi, Y. Zorumski, C.F. Removal of extracellular calcium after conditioning stimulation disrupts long-term potentiation in the CA1 region of rat hippocampal slices. Neuroscience 1997, 76: 1113-1119.
45. Michaelis, E.K. Molecular biology of glutamate receptors in the central nervous system and their role in excitotoxicity, oxidative stress and aging. Prog. Neurobiol. 1998, 54: 369-415.
46. Lipton, S.A. Chen, H.S. Paradigm shift in neuroprotective drug development: clinically tolerated NMDA receptor inhibition by memantine. Cell Death Differ. 2004, 11: 18-20.
47. Reisberg, B., Doody, R., Stoffler, A., Schmitt, F., Ferris, S. Mobins, H.J. Memantine in moderate-to-severe Alzheimer's disease. N. Engl. J. Med. 2003, 348: 1333-1341.
48. Winblad, B. Poritis, N. Memantine in severe dementia: results of the 9M-Best Study (Benefit and efficacy in severely demented patients during treatment with memantine). Int. J. Geriatr. Psychiatry 1999, 14: 135-146.
49. Tariot, P.N., Farlow, MR., Grossberg, G.T., Graham, S.M., McDonald, S., Gergel, I. Group., M.S. Memantme treatment in patients with moderate to severe Alzheimer disease already receiving donepezil: a randomized controlled trial. JAMA 2004, 291: 317-324.
50. Peskind, E.R., Potkin, S.G., Pomara, N., Ott, B.R., Graham, S.M., Olin, J.J. McDonald, S. Memantine treatment in mild to moderate Alzheimer disease: a 24-week randomized, controlled trial. Am. J. Geriatr. Psychiatry 2006, 14: 704-715.
51. Gauthier, S., Wirth, Y. Mobius, H.J. Effects of memantine on behavioural symptoms in Alzheimer's disease patients: an analysis of the Neuropsychiatric Inventory (NPI) data of two randomised, controlled studies. Int. J. Geriatr. Psychiatry 2005, 20: 459-464.
52. Behl, C. Alzheimer's disease and oxidative stress: implications for novel therapeutic approaches. Prog. Neurobiol. 1999, 57: 301-323.
53. Sano, M., Ernesto, C., Thomas, R.G., Klauber, MR., Schafer, K., Grundman, M., Woodbury, P., Growdon, J., Cotman, C.W., Pfeiffer, E., Schneider, L.S. Thal, L.J. A controlled trial of selegiline, alpha-tocopherol, or both as treatment for Alzheimer's disease. The Alzheimer's Disease Cooperative Study. N. Engl. J. Med. 1997, 336: 1216-1222.
54. Miller, ER., 3rd, Pastor-Barriuso, R., Dalal, D., Riemersma, R.A., Appel, L.J. Guallar, E. Meta-Analysis: High-Dosage Vitamin E Supplementation May Increase All-Cause Mortality. Ann. Intern. Med. 2005, 142: 37-46.
55. Effect of deprenyl on the progression of disability in early Parkinson's disease. The Parkinson Study Group. N. Engl. J. Med. 1989, 321: 1364-1371.
56. Petersen, R.C., Thomas, R.G., Grundman, M., Bennett, D., Doody, R., Ferris, S., Galasko, D., Jin, S., Kaye, J., Levey, A., Pfeiffer, E., Sano, M., van Dyck, C.H. Thal, L.J. Vitamin E and donepezil for the treatment of mild cognitive impairment. N. Engl. J Med. 2005, 352: 2379-2388.
57. Luo, Y., Smith, J.V., Paramasivam, V., Burdick, A., Curry, K.J., Buford, J.P., Khan, I., Netzer, W.J., Xu, H. Butko, P. Inhibition of amyloid-beta aggregation and caspase-3 activation by the Ginkgo biloba extract EGb761. Proc. Natl. Acad. Sci. U. S. A. 2002, 99: 12197-12202.
58. Solomon, P.R., Adams, F., Silver, A., Zimmer, J. DeVeaux, R. Ginkgo for memory enhancement: a randomized controlled trial. JAMA 2002, 288: 835-840.
59. Le Bars, P.L., Katz, M.M., Berman, N., Itil, T.M., Freedman, A.M. Schatzberg, A.F. A placebo-controlled, double-blind, randomized trial of an extract of Ginkgo biloba for dementia. North American EGb Study Group. JAMA 1997, 278: 1327-1332.
60. Etminan, M., Gill, S. Samii, A. Effect of non-steroidal anti-inflammatory drugs on risk of Alzheimer's disease: systematic review and meta-analysis of observational studies. BMJ 2003, 327: 128.
61. in t' Veld, B.A., Ruitenberg, A., Holman, A., Launer, L.J., van Duijn, C.M., Stijnen, T., Breteler, M.M. Stricker, B.H. Nonsteroidal antiflammatory drugs and the risk of Alzheimer's disease. N. Engl. J Med. 2001, 345: 1515-1521.
62. Zandi, P.P., Anthony, J.C., Hayden, K.M., Mehta, K., Mayer, L. Breitner, J.C. Reduced incidence of AD with NSAID but not H2 receptor antagonists: the Cache County Study. Neurology 2002, 59: 880-886.
63. Beard, C.M., Waring, S.C., O'Brien, P.C., Kurland, L.T. Kokmen, E. Nonsteroidal anti-inflammatory drug use and Alzheimer's disease: a case-control study in Rochester, Minnesota, 1980 through 1984. Mayo Clin. Proc. 1998, 73: 951-955.
64. Breitner, J.C., Gau, B.A., Welsh, K.A., Plassman, B.L., McDonald, W.M., Helms, M.J. Anthony, J.C. Inverse association of anti-inflammatory treatments and Alzheimer's disease: initial results of a co-twin control study. Neurology 1994, 44: 227-232.
65. McGeer, P.L., Schulzer, M. McGeer, E.G. Arthritis and anti-inflammatory agents as possible protective factors for Alzheimer's disease: a review of 17 epiderniologic studies. Neurology 1996, 47: 425-432.
66. Aisen, P.S., Schafer, K.A., Grundman, M., Pfeiffer, E., Sano, M., Davis, K.L., Farlow, MR., Jin, S., Thomas, R.G. Thal, L.J. Effects of rofecoxib or naproxen vs placebo on Alzheimer disease progression: a randomized controlled trial. JAMA 2003, 289: 2819-2826.
67. Van Gool, W.A., Weinstein, H.C., Scheltens, P., Walstra, G.J. Scheltens, P.K. Effect of hydroxychloroquine on progression of dementia in early Alzheimer's disease: an 18-month randomised, double-blind, placebo-controlled study. Lancet 2001, 358: 455-460.
68. Aisen, P.S., Davis, K.L., Berg, J.D., Schafer, K., Campbell, K., Thomas, R.G., Weiner, M.F., Farlow, M.R., Sano, M., Grundman, M. Thal, L.J. A randomized controlled trial of prednisone in Alzheimer's disease. Alzheimer's Disease Cooperative Study. Neurology 2000, 54: 588-593.
69. Scharf, S., Mander, A., Ugoni, A., Vajda, F. Christophidis, N. A double-blind, placebo-controlled trial of diclofenac/misoprostol in Alzheimer's disease. Neurology 1999, 53: 197-201.
70. Rogers, J., Kirby, L.C., Hempelman, S.R., Berry, D.L., McGeer, P.L., Kaszniak, AW., Zalinski, J., Cofield, M., Mansukhani, L., Willson, P., Kogan, F. Clinical trial of indomethacin in Alzheimer's disease. Neurology 1993, 43: 1609-1611.
71. Aisen, P.S., Schmeidler, J. Pasinetti, G.M. Randomized pilot study of nimesulide treatment in Alzheimer's disease. Neurology 2002, 58: 1050-1054.
72. Cohen-Mansfield, J. Nonpharmacologic interventions for inappropriate behaviors in dementia: a review, summary, and critique. Am. J. Geriatr. Psychiatry 2001, 9: 361-381.
73. Lyketsos, C.G., DelCampo, L., Steinberg, M., Miles, Q., Steele, C.D., Munro, C., Baker, A.S., Sheppard, J.M., Frangakis, C., Brandt, J. Rabins, P.V. Treating depression in Alzheimer disease: efficacy and safety of sertraline therapy, and the benefits of depression reduction: the DIADS. Arch. Gen. Psychiatry 2003, 60: 737-746.
74. Zubenko, G.S., Zubenko, W.N., McPherson, S., Spoor, E., Marin, D.B., Farlow, M.R., Smith, G.E., Geda, Y.E., Cummings, J.L., Petersen, R.C. Sunderland, T. A collaborative study of the emergence and clinical features of the major depressive syndrome of Alzheimer's disease. Am. J. Psychiatry 2003, 160: 857-866.
75. Lyketsos, C.G., Sheppard, J.M., Steele, C.D., Kopunek, S., Steinberg, M., Baker, A.S., Brandt, J. Rabins, P.V. Randomized, placebo-controlled, double-blind clinical trial of sertraline in the treatment of depression complicating Alzheimer's disease: initial results from the Depression in Alzheimer's Disease study. Am. J Psychiatry. 2000, 157: 1686-1689.
76. Taragano, F.E., Lyketsos, C.G., Mangone, C.A., Allegri, R.F. Comesana-Diaz, E. A double-blind, randomized, fixed-dose trial of fluoxetine vs. amitriptyline in the treatment of major depression complicating Alzheimer's disease. Psychosomatics 1997, 38: 246-252.
77. Nyth, A.L. Gottfries, C.G. The clinical efficacy of citalopram in treatment of emotional disturbances in dementia disorders. A Nordic multicentre study. Br. J Psychiatry 1990, 157: 894-901.
78. Nyth, A.L., Gottfries, C.G., Lyby, K., Smedegaard-Andersen, L., Gylding-Sabroe, J., Kristensen, M., Refsum, H.E., Ofsti, E., Eriksson, S. Syversen, S. A controlled multicenter clinical study of citalopram and placebo in elderly depressed patients with and without concomitant dementia. Acta Psychiatr. Scand. 1992, 86: 138-145.
79. Katona, C.L., Hunter, B.N. Bray, J. A double-blind comparison of the efficacy and safely of paroxetine and imipramine in the treatment of depression with dementia. Int. J Geriatr. Psychiatry 1998, 13: 100-108.
80. Petracca, G., Teson, A., Chemerinski, E., Leiguarda, R. Starkstein, S.E. A double-blind placebo-controlled study of clomipramine in depressed patients with Alzheimer's disease. J Neuropsychiatry Clin. Neurosci. 1996, 8: 270-275.
81. Roth, M., Mountjoy, C.Q. Amrein, R. Moclobemide in elderly patients with cognitive decline and depression: an international double-blind, placebo-controlled trial. Br. J Psychiatry 1996, 168: 149-157.
82. Reifler, B.V., Teri, L., Raskind, M., Veith, R., Barnes, R., White, E. McLean, P. Double-blind trial of imipramine in Alzheimer's disease patients with and without depression. Am. J Psychiatry 1989, 146: 45-49.
83. Magai, C., Kennedy, G., Cohen, C.I. Gomberg, D. A controlled clinical trial of sertraline in the treatment of depression in nursing home patients with late-stage Alzheimer's disease. Am. J. Geriatr. Psychiatry 2000, 8: 66-74.
84. Petracca, G.M., Chemerinski, E. Starkstein, S.E. A double-blind, placebo-controlled study of fluoxetine in depressed patients with Alzheimer's disease. Int. Psychogeriatr. 2001, 13: 233-240.
85. Lyketsos, C.G. Lee, H.B. Diagnosis and treatment of depression in Alzheimer's disease. A practical update for the clinician. Dement. Geriatr. Cogn. Disord. 2004, 17: 55-64.
86. Lee, P.E., Gill, S.S., Freedman, M., Bronskill, S.E., Hillmer, M.P. Rochon, P.A. Atypical antipsychotic drugs in the treatment of behavioural and psychological symptoms of dementia: systematic review. BMJ 2004, 329: 75.
87. Brodaty, H., Ames, D., Snowdon, J., Woodward, M., Kirwan, J., Clarnette, R., Lee, E., Lyons, B. Grossman, F. A randomized placebo-controlled trial of risperidone for the treatment of aggression, agitation, and psychosis of dementia. J Clin. Psychiatry 2003, 64: 134-143.
88. Street, J.S., Clark, W.S., Gannon, K.S., Cummings, J.L., Bymaster, F.P., Tamura, R.N., Mitan, S.J., Kadam, D.L., Sanger, T.M., Feldman, P.D., Tollefson, G.D. Breier, A. Olanzapine treatment of psychotic and behavioral symptoms in patients with Alzheimer disease in nursing care facilities: a double-blind, randomized, placebo-controlled trial. The HGEU Study Group. Arch. Gen. Psychiatry 2000, 57: 968-976.
89. Katz, I.R., Jeste, D.V., Mintzer, J.E., Clyde, C., Napolitano, J. Brecher, M. Comparison of risperidone and placebo for psychosis and behavioral disturbances associated with dementia: a randomized, double-blind trial. Risperidone Study Group. J. Clin. Psychiatry 1999, 60: 107-115.
90. De Deyn, P.P., Rabheru, K., Rasmussen, A., Bocksberger, J.P., Dautzenberg, P.L., Eriksson, S. Lawlor, B.A. A randomized trial of risperidone, placebo, and haloperidol for behavioral symptoms of dementia. Neurology 1999, 53: 946-955.
91. Street, J.S., Clark, W.S., Kadam, D.L., Mitan, S.J., Juliar, B.E., Feldman, P.D. Breier, A. Long-term efficacy of olanzapine in the control of psychotic and behavioral symptoms in nursing home patients with Alzheimer's dementia. Int. J. Geriatr. Psychiatry 2001, 16 Suppl 1: S62-70.
92. Scharre, D.W. Chang, S.I. Cognitive and behavioral effects of quetiapine in Alzheimer disease patients. Alzheimer Dis. Assoc. Disord. 2002, 16: 128-130.
93. Fujikawa, T., Takahashi, T., Kinoshita, A., Kajiyama, H., Kurata, A., Yamashita, H. Yamawaki, S. Quetiapine treatment for behavioral and psychological symptoms in patients with senile dementia of Alzheimer type. Neuropsychobiology 2004, 49: 201-204.
94. Tariot, P.N., Schneider, L., Katz, I.R., Mintzer, J.E., Street, J., Copenhaver, M. Williams-Hughes, C. Quetiapine treatment of psychosis associated with dementia: a double-blind, randomized, placebo-controlled clinical trial. Am. J Geriatr. Psychiatry 2006, 14: 767-776.
95. Kurlan, R., Cummings, J., Raman, R. Thal, L. Quetiapine for agitation or psychosis in patients with dementia and parkinsonism. Neurology 2007, 68: 1356-1363.
96. Schneider, L.S., Tariot, P.N., Dagerman, K.S., Davis, S.M., Hsiao, J.K., Ismail, M.S., Lebowitz, B.D., Lyketsos, C.G., Ryan, J.M., Stroup, T.S., Sultzer, D.L., Weintraub, D. Lieberman, J.A. Effectiveness of atypical antipsychotic drugs in patients with Alzheimer's disease. N. Engl. J. Med. 2006, 355: 1525-1538.
97. Chan, W.C., Lam, L.C., Choy, C.N., Leung, V.P., Li, S.W. Chiu, H.F. A double-blind randomised comparison of risperidone and haloperidol in the treatment of behavioural and psychological symptoms in Chinese dementia patients. Int. J. Geriatr. Psychiatry 2001, 16: 1156-1162.
98. Schneider, L.S., Dagerman, K.S. Insel, P. Risk of death with atypical antipsychotic drug treatment for dementia: meta-analysis of randomized placebo-controlled trials. JAMA 2005, 294: 1934-1943.
99. Schneider, L.S., Dagerman, K. Insel, P.S. Efficacy and adverse effects of atypical antipsychotics for dementia: meta-analysis of randomized, placebo-controlled trials. Am. J. Geriatr. Psychiatry 2006, 14: 191-210.
100. Citron, M. Strategies for disease modification in Alzheimer's disease. Nat. Rev. Neurosci. 2004, 5: 677-685.
101. Dovey, H.F., John, V., Anderson, J.P., Chen, L.Z., de Saint Andrieu, P., Fang, L.Y., Freedman, S.B., Folmer, B., Goldbach, E., Holsztynska, E.J., Hu, K.L., Johnson-Wood, K.L., Kennedy, S.L., Kholodenko, D., Knops, J.E., Latimer, L.H., Lee, M., Liao, Z., Lieberburg, I.M., Motter, R.N., Mutter, L.C., Nietz, J., Quinn, K.P., Sacchi, K.L., Seubert, P.A., Shopp, G.M., Thorsett, E.D., Tung, J.S., Wu, J., Yang, S., Yin, C.T., Schenk, D.B., May, P.C., Altstiel, L.D., Bender, M.H., Boggs, L.N., Britton, T.C., Clemens, J.C., Czilli, D.L., Dieckman-McGinty, D.K., Droste, J.J., Fuson, K.S., Gitter, B.D., Hyslop, P.A., Johnstone, E.M., Li, W.Y., Little, S.P., Mabry, T.E., Miller, F.D. Audia, J.E. Functional gamma-secretase inhibitors reduce beta-amyloid peptide levels in brain. J. Neurochem. 2001, 76: 173-181.
102. De Strooper, B., Annaert, W., Cupers, P., Saftig, P., Craessaerts, K., Mumm, J.S., Schroeter, E.H., Schrijvers, V., Wolfe, M.S., Ray, W.J., Goate, A. Kopan, R. A presenilin-1-dependent gamma-secretase-like protease mediates release of Notch intracellular domain. Nature 1999, 398: 518-522.
103. Wong, G.T., Manfra, D., Poulet, F.M., Zhang, Q., Josien, H., Bara, T., Engstrom, L., Pinzon-Ortiz, M., Fine, J.S., Lee, H.J., Zhang, L., Higgins, G.A. Parker, E.M. Chronic treatment with the gamma-secretase inhibitor LY-411,575 inhibits β-amyloid peptide production and alters lymphopoiesis and intestinal cell differentiation. J. Biol. Chem. 2004, 279: 12876-12882.
104. Siemers, E.R., Quinn, J.F., Kaye, J., Farlow, M.R., Porsteinsson, A., Tariot, P., Zoulnouni, P., Galvin, J.E., Holtzman, D.M., Knopman, D.S., Satterwhite, J., Gonzales, C., Dean, R.A. May, P.C. Effects of a gamma-secretase inhibitor in a randomized study of patients with Alzheimer disease. Neurology 2006, 66: 602-604.
105. Vassar, R., Bennett, B.D., Babu-Khan, S., Kahn, S., Mendiaz, E.A., Denis, P., Teplow, D.B., Ross, S., Amarante, P., Loeloff, R., Luo, Y., Fisher, S., Fuller, J., Edenson, S., Lile, J., Jarosinski, M.A., Biere, A.L., Curran, E., Burgess, T., Louis, J.C., Collins, F., Treanor, J., Rogers, G. Citron, M. Beta-secretase cleavage of Alzheimer's amyloid precursor protein by the transmembrane aspartic protease BACE. Science 1999, 286: 735-741.
106. Yan, R., Bienkowski, M.J., Shuck, M.E., Miao, H., Tory, M.C., Pauley, A.M., Brashier, J.R., Stratman, N.C., Mathews, W.R., Buhl, A.E., Carter, D.B., Tomasselli, A.G., Parodi, L.A., Heinrikson, R.L. Gurney, M.E. Membrane-anchored aspartyl protease with Alzheimer's disease beta-secretase activity. Nature 1999, 402: 533-537.
107. Citron, M. β-secretase as a target for the treatment of Alzheimer's disease. J. Neurosci. Res. 2002, 70: 373-379.
108. Luo, Y., Bolon, B., Kahn, S., Bennett, B.D., Babu-Khan, S., Denis, P., Fan, W., Kha, H., Zhang, J., Gong, Y., Martin, L., Louis, J.C., Yan, Q., Richards, W.G., Citron, M. Vassar, R. Mice deficient in BACE1, the Alzheimer's β-secretase, have normal phenotype and abolished beta-amyloid generation. Nat. Neurosci. 2001, 4: 231-232.
109. Fukumoto, H., Rosene, D.L., Moss, M.B., Raju, S., Hyman, B.T. Irizarry, M.C. β-secretase activity increases with aging in human, monkey, and mouse brain. Am. J. Pathol. 2004, 164: 719-725.
110. Schenk, D., Barbour, R., Dunn, W., Gordon, G., Grajeda, H., Guido, T., Hu, K., Huang, J., Johnson-Wood, K., Khan, K., Kholodenko, D., Lee, M., Liao, Z., Lieberburg, I., Motter, R., Mutter, L., Soriano, F., Shopp, G., Vasquez, N., Vandevert, C., Walker, S., Wogulis, M., Yednock, T., Games, D. Seubert, P. Immunization with amyloid-β attenuates Alzheimer-disease-like pathology in the PDAPP mouse. Nature 1999, 400: 173-177.
111. Morgan, D., Diamond, D.M., Gottschall, P.E., Ugen, K.E., Dickey, C., Hardy, J., Duff, K., Jantzen, P., DiCarlo, G., Wilcock, D., Connor, K., Hatcher, J., Hope, C., Gordon, M. Arendash, G.W. Aβ peptide vaccination prevents memory loss in an animal model of Alzheimer's disease. Nature 2000, 408: 982-985.
112. Janus, C., Pearson, J., McLaurin, J., Mathews, P.M., Jiang, Y., Schmidt, S.D., Chishti, M.A., Horne, P., Heslin, D., French, J., Mount, H.T., Nixon, R.A., Mercken, M., Bergeron, C., Fraser, P.E., St George-Hyslop, P. Westaway, D. Aβ peptide immunization reduces behavioural impairment and plaques in a model of Alzheimer's disease. Nature 2000, 408: 979-982.
113. DeMattos, R.B., Bales, K.R., Cummins, D.J., Dodart, J.C., Paul, S.M. Holtzman, D.M. Peripheral anti-A beta antibody alters CNS and plasma A beta clearance and decreases brain A beta burden in a mouse model of Alzheimer's disease. Proc. Natl. Acad. Sci. U. S. A. 2001, 98: 8850-8855.
114. Dodart, J.C., Bales, K.R., Gannon, K.S., Greene, S.J., DeMattos, R.B., Mathis, C., DeLong, C.A., Wu, S., Wu, X., Holtzman, D.M. Paul, S.M. Immunization reverses memory deficits without reducing brain Aβ burden in Alzheimer's disease model. Nat. Neurosci. 2002, 5: 452-457.
115. Gilman, S., Koller, M., Black, R.S., Jenkins, L., Griffith, S.G., Fox, N.C., Eisner, L., Kirby, L., Rovira, M.B., Forette, F. Orgogozo, J.M. Clinical effects of Abeta immunization (AN1792) in patients with AD in an interrupted trial. Neurology 2005, 64: 1553-1562.
116. Nicoll, J.A., Wilkinson, D., Holmes, C., Steart, P., Markham, H. Weller, R.O. Neuropathology of human Alzheimer disease after immunization with amyloid-β peptide: a case report. Nat. Med. 2003, 9: 448-452.
117. Ferrer, I., Boada Rovira, M., Sanchez Guerra, M.L., Rey, M.J. Costa-Jussa, F. Neuropathology and pathogenesis of encephalitis following amyloid-beta immunization in Alzheimer's disease. Brain Pathol. 2004, 14: 11-20.
118. Aisen, P.S., Saumier, D., Briand, R., Laurin, J., Gervais, F., Tremblay, P. Garceau, D. A Phase II study targeting amyloid-beta with 3APS in mild-to-moderate Alzheimer disease. Neurology 2006, 67: 1757-1763.